| Literature DB >> 30774816 |
Habib Malekpour1, Mohammad Hossein Heidari2, Reza Vafaee3, Hamideh Moravvej Farshi4, Mahsa Khodadoostan5.
Abstract
AIM: The aim of this research was to find a clear molecular view of dysplasia via network analysis.Entities:
Keywords: Colon cancer; High grade dysplasia; Interactome; Transcriptome
Year: 2018 PMID: 30774816 PMCID: PMC6347998
Source DB: PubMed Journal: Gastroenterol Hepatol Bed Bench ISSN: 2008-2258
Figure 1Gene expression profiles of 6 HGD mice and 3 normal controls
Hub nodes of HGD network
| R | display name | Description | Degree | BC | CC |
|---|---|---|---|---|---|
| 1 | GAPDH | glyceraldehyde-3-phosphate dehydrogenase | 67 | 0.059 | 0.706 |
| 2 | IL6 | interleukin 6 (interferon, beta 2) | 64 | 0.021 | 0.677 |
| 3 | TNF | tumor necrosis factor | 63 | 0.025 | 0.673 |
| 4 | INS | Insulin | 63 | 0.058 | 0.681 |
| 5 | TGFB1 | transforming growth factor, beta 1 | 58 | 0.071 | 0.657 |
| 6 | IL8 | interleukin 8 | 58 | 0.026 | 0.653 |
| 7 | ALB | Albumin | 58 | 0.019 | 0.653 |
| 8 | CCL2 | chemokine (C-C motif) ligand 2 | 58 | 0.012 | 0.657 |
| 9 | AKT1 | v-akt murine thymoma viral oncogene homolog 1 | 58 | 0.046 | 0.661 |
| 10 | VEGFA | vascular endothelial growth factor A | 57 | 0.029 | 0.649 |
| 11 | IL1B | interleukin 1, beta | 56 | 0.024 | 0.646 |
| 12 | JUN | jun proto-oncogene | 56 | 0.021 | 0.661 |
| 13 | PRDM10 | PR domain containing 10 | 56 | 0.027 | 0.657 |
| 14 | IL10 | interleukin 10 | 54 | 0.009 | 0.638 |
| 15 | IL4 | interleukin 4 | 54 | 0.013 | 0.638 |
| 16 | CSF2 | colony stimulating factor 2 (granulocyte-macrophage) | 54 | 0.012 | 0.638 |
| 17 | MMP9 | matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | 53 | 0.005 | 0.631 |
| 18 | TLR4 | toll-like receptor 4 | 52 | 0.008 | 0.631 |
| 19 | DECR1 | 2,4-dienoyl CoA reductase 1, mitochondrial | 51 | 0.046 | 0.635 |
| 20 | SRC | v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) | 51 | 0.015 | 0.631 |
| 21 | VCAM1 | vascular cell adhesion molecule 1 | 51 | 0.009 | 0.628 |
| 22 | NOS3 | nitric oxide synthase 3 (endothelial cell) | 50 | 0.028 | 0.628 |
| 23 | TP53 | tumor protein p53 | 49 | 0.051 | 0.632 |
| 24 | CXCR4 | chemokine (C-X-C motif) receptor 4 | 48 | 0.007 | 0.608 |
| 25 | ITGAM | integrin, alpha M (complement component 3 receptor 3 subunit) | 48 | 0.011 | 0.611 |
| 26 | IL13 | interleukin 13 | 48 | 0.008 | 0.611 |
| 27 | IL17A | interleukin 17A | 47 | 0.025 | 0.595 |
| 28 | TLR2 | toll-like receptor 2 | 47 | 0.014 | 0.604 |
| 29 | MAPK1 | mitogen-activated protein kinase 1 | 47 | 0.019 | 0.614 |
| 30 | EGFR | epidermal growth factor receptor | 46 | 0.047 | 0.604 |
| 31 | F2 | coagulation factor II (thrombin) | 45 | 0.015 | 0.608 |
| 32 | EGF | epidermal growth factor | 45 | 0.012 | 0.604 |
| 33 | CXCL12 | chemokine (C-X-C motif) ligand 12 | 45 | 0.003 | 0.592 |
| 34 | CD44 | CD44 molecule (Indian blood group) | 44 | 0.004 | 0.598 |
| 35 | IL18 | interleukin 18 (interferon-gamma-inducing factor) | 43 | 0.003 | 0.579 |
| 36 | CAT | Catalase | 43 | 0.040 | 0.601 |
| 37 | IGF1 | insulin-like growth factor 1 (somatomedin C) | 43 | 0.007 | 0.592 |
| 38 | NOS2 | nitric oxide synthase 2, inducible | 43 | 0.014 | 0.598 |
| 39 | SPP1 | secreted phosphoprotein 1 | 41 | 0.021 | 0.577 |
| 40 | MMP2 | matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) | 41 | 0.002 | 0.582 |
| 41 | ITGAX | integrin, alpha X (complement component 3 receptor 4 subunit) | 40 | 0.006 | 0.562 |
| 42 | MYD88 | myeloid differentiation primary response 88 | 39 | 0.032 | 0.562 |
| 43 | CCR5 | chemokine (C-C motif) receptor 5 (gene/pseudogene) | 37 | 0.002 | 0.554 |
| 44 | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | 36 | 0.008 | 0.559 |
| 45 | CCR2 | chemokine (C-C motif) receptor 2 | 35 | 0.001 | 0.549 |
| 46 | CXCR2 | chemokine (C-X-C motif) receptor 2 | 34 | 0.001 | 0.538 |
Figure 2Pathways related to the hubs of dysplasia network. The involved genes in each process are presented in the bottom of figure. Except the green colored one, the other pathways are grouped in one cluster. Sequence of genes rows is corresponded with pathways up to down, respectively
Hub nodes that are involved in the 12 pathways
| R | Gene name | Number of relevant pathways |
|---|---|---|
| 1 | IL1B, IL6 | 11 |
| 2 | TNF, TRL4 | 10 |
| 3 | JUN | 9 |
| 4 | CXCL8, MPK1 | 8 |
| 5 | TLR2, TGFB1 | 7 |
| 6 | NOS2, MYD88, IL10 | 6 |
| 7 | CCL2 | 5 |
| 8 | CSF2, IL18, AKT1 | 4 |
| 9 | ITGAM, VEGFA, IL17A, IL4 | 3 |
| 10 | NOS3, VCAM1, IL13 | 2 |
| 11 | EGF, EGFR, GAPDH, IGF1, INS, MMP2, MMP9, CXCL12, SPP1 | 1 |
Figure 3Protein cluster analysis of hub nodes via ClusterOne application is shown. The cluster was elected based on at least ten genes per cluster
Figure 4Cluster 1 PPI network. The two out layer nodes are displayed in gray color